Phase I Study of Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC
Phase of Trial: Phase I
Latest Information Update: 09 Feb 2019
Price : $35 *
At a glance
- Drugs Ceritinib (Primary) ; Docetaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Oct 2018 Planned End Date changed from 1 Aug 2024 to 1 Oct 2024.
- 31 Oct 2018 Planned primary completion date changed from 1 Aug 2023 to 1 Oct 2023.
- 31 Oct 2018 Status changed from not yet recruiting to recruiting.